Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSGBR-0905)

H. R. Kim, K. H. Jung, S. A. Im, Y. H. Im, S. Y. Kang, K. H. Park, S. Lee, S. B. Kim, K. H. Lee, J. S. Ahn, S. I. Kim, J. H. Sohn

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)

Abstract

Background: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer. Patients and methods: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)- negative, stage II/III breast cancer received six cycles of 75 mg/m2 docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN). Results: Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13% (n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery. Conclusions: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery.

Original languageEnglish
Pages (from-to)1485-1490
Number of pages6
JournalAnnals of Oncology
Volume24
Issue number6
DOIs
Publication statusPublished - 2013 Jun

Bibliographical note

Funding Information:
This work was supported by Astellas, Boryung, F. Hoffman-La Roche Ltd and Sanofi-Aventis [no grant numbers]. The sponsors approved the protocol, but were not involved in data collection, analysis or interpretation. All authors had the opportunity to comment on the draft manuscript and to review and approve the final version. HRK and JS had full access to the study data. JS took final responsibility for the decision to submit for publication.

Keywords

  • Bevacizumab
  • Carboplatin
  • Docetaxel
  • Neoadjuvant chemotherapy
  • Pathological complete response
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSGBR-0905)'. Together they form a unique fingerprint.

Cite this